Infections due to carbapenemase-producing bacteria, clinical burden, and impact of screening strategies on outcome
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
OBJECTIVES: To characterize the risk factors, impact of screening, and clinical burden of colonization and/or infection by carbapenemase-producing bacteria (CPB) in hospitalized patients.
METHOD: Retrospective study in a tertiary care hospital between 2008 and 2016.
RESULTS: Among 88 included patients, 41% were colonized, 59% developed an infection, and 69% of all cases were hospital-acquired. Risk factors for CPB contamination included recent invasive medical device (94% of patients), antibiotic therapy (82%), travel abroad (17%), and hospitalization (>50%) with 80% of all patients with underlying chronic condition. Intestinal carriage represented 89% of all colonization cases and 50% of infections were located in the urinary tract. The recent use of mechanical ventilation devices was significantly more observed in infected patients than colonized patients. The most frequent CPB was Klebsiella pneumoniae and the most frequent carbapenemase was OXA-48. Overall mortality rate was 19%. Prevalence of CPB detection in intensive care units (ICU) based on systematical rectal screen swab upon admission remained <0.5%. The infected/colonized ratio (CPB colonization cases evolving into an infection) was 23%. The time between CPB infection diagnosis and start of appropriate antimicrobial therapy increased from 1 day in previously screened patients with positive CPB to 4 days in patients with previous negative or absent screening.
CONCLUSION: Our results emphasize the importance of CPB screening in all ICU patients and in at-risk patients hospitalized in other units, to allow earlier adequate antibiotic therapy in case of infection which occurred in 23% of the colonized patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Medecine et maladies infectieuses - 50(2020), 8 vom: 28. Nov., Seite 658-664 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abramowicz, Louise [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.10.2021 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.medmal.2019.12.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306302969 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306302969 | ||
| 003 | DE-627 | ||
| 005 | 20231225123050.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medmal.2019.12.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1020.xml |
| 035 | |a (DE-627)NLM306302969 | ||
| 035 | |a (NLM)32035722 | ||
| 035 | |a (PII)S0399-077X(20)30024-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abramowicz, Louise |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Infections due to carbapenemase-producing bacteria, clinical burden, and impact of screening strategies on outcome |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.10.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVES: To characterize the risk factors, impact of screening, and clinical burden of colonization and/or infection by carbapenemase-producing bacteria (CPB) in hospitalized patients | ||
| 520 | |a METHOD: Retrospective study in a tertiary care hospital between 2008 and 2016 | ||
| 520 | |a RESULTS: Among 88 included patients, 41% were colonized, 59% developed an infection, and 69% of all cases were hospital-acquired. Risk factors for CPB contamination included recent invasive medical device (94% of patients), antibiotic therapy (82%), travel abroad (17%), and hospitalization (>50%) with 80% of all patients with underlying chronic condition. Intestinal carriage represented 89% of all colonization cases and 50% of infections were located in the urinary tract. The recent use of mechanical ventilation devices was significantly more observed in infected patients than colonized patients. The most frequent CPB was Klebsiella pneumoniae and the most frequent carbapenemase was OXA-48. Overall mortality rate was 19%. Prevalence of CPB detection in intensive care units (ICU) based on systematical rectal screen swab upon admission remained <0.5%. The infected/colonized ratio (CPB colonization cases evolving into an infection) was 23%. The time between CPB infection diagnosis and start of appropriate antimicrobial therapy increased from 1 day in previously screened patients with positive CPB to 4 days in patients with previous negative or absent screening | ||
| 520 | |a CONCLUSION: Our results emphasize the importance of CPB screening in all ICU patients and in at-risk patients hospitalized in other units, to allow earlier adequate antibiotic therapy in case of infection which occurred in 23% of the colonized patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adequate antibiotic therapy | |
| 650 | 4 | |a Bactérie productrice de carbapénémases | |
| 650 | 4 | |a Carbapenem resistance | |
| 650 | 4 | |a Carbapenemase-producing bacteria | |
| 650 | 4 | |a Dépistage rectal | |
| 650 | 4 | |a Enterobacteriaceae | |
| 650 | 4 | |a Entérobactéries | |
| 650 | 4 | |a Rectal screening | |
| 650 | 4 | |a Résistance aux carbapénèmes | |
| 650 | 4 | |a Traitement antibiotique approprié | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a beta-Lactamases |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 650 | 7 | |a carbapenemase |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 700 | 1 | |a Gerard, Michèle |e verfasserin |4 aut | |
| 700 | 1 | |a Martiny, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Delforge, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a De Wit, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Konopnicki, Deborah |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medecine et maladies infectieuses |d 1983 |g 50(2020), 8 vom: 28. Nov., Seite 658-664 |w (DE-627)NLM121109992 |x 1769-6690 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2020 |g number:8 |g day:28 |g month:11 |g pages:658-664 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medmal.2019.12.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2020 |e 8 |b 28 |c 11 |h 658-664 | ||